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Use of Herbal Products and Potential
Interactions in Patients With Cardiovascular Diseases
Ara Tachjian, MD,* Viqar Maria, MBBS,* Arshad Jahangir, MD†
Rochester, Minnesota; and Scottsdale, Arizona
More than 15 million people in the U.S. consume herbal remedies or high-dose vitamins. The number of visits to
providers of complementary and alternative medicine exceeds those to primary care physicians, for annual out-
of-pocket costs of $30 billion. Use of herbal products forms the bulk of treatments, particularly by elderly people
who also consume multiple prescription medications for comorbid conditions, which increases the risk of ad-
verse herb-drug-disease interactions. Despite the paucity of scientific evidence supporting the safety or efficacy
of herbal products, their widespread promotion in the popular media and the unsubstantiated health care claims
about their efficacy drive consumer demand. In this review, we highlight commonly used herbs and their interac-
tions with cardiovascular drugs. We also discuss health-related issues of herbal products and suggest ways to
improve their safety to better protect the public from untoward effects. (J Am Coll Cardiol 2010;55:515–25)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.074t
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terbal supplements have been used for thousands of years
n the East and have had a recent resurgence in popularity
mong consumers in the West. More than 15 million
eople in the U.S. consume herbal remedies or high-dose
itamins, and the total number of visits to complementary
nd alternative medicine (CAM) providers far exceeds those
o primary physicians (Fig. 1A), amounting to more than
34 billion out-of-pocket costs for CAM annually (1)
Fig. 1B). Of the $37.1 billion spent for weight-loss
roducts in 2001, $17.7 billion was for dietary and herbal
eight-loss supplements, a number projected to increase by
% to 7% per year (2). Multiple factors contribute to the
ncreased use of CAM, including the obesity epidemic, the
revalence of chronic disorders and pain syndromes, anxi-
ty, depression (Fig. 1C), the general desire for good health
nd wellness, disease prevention, the increasing cost of
onventional medicines, and the traditional belief that
AM is safer and more effective than prescription drugs
hat commonly have adverse effects.
Herbs, generally defined as any form of plant or plant
roduct, constitute the largest proportion of CAM use in
he U.S. (Fig. 2). Because herbs are regarded as food
roducts, they are not subject to the same scrutiny and
egulation as traditional medications. As a result, manufac-
rom the *Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota;
nd the †Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, Arizona. Dr.
achjian is a visiting physician at the Division of Cardiovascular Diseases, Mayo
linic, Rochester, Minnesota. Dr. Jahangir is supported in part by grants from the
ational Institute on Aging (AG21201); the National Heart, Lung, and Blood
nstitute (HL089542); the Mayo Clinic Marriott Mitochondrial Medicine Award;i
nd the Angel and Paul Harvey Cardiovascular Research Endowment.
Manuscript received June 11, 2008; accepted July 30, 2009.urers are exempt from pre-market safety and efficacy testing
efore the release of an herbal product and from any
ost-marketing surveillance. Although herbal remedies are
erceived as being natural and therefore safe, many have
dverse effects that can sometimes produce life-threatening
onsequences.
Despite the paucity of scientific evidence about the safety
r efficacy of herbal products, widespread promotion of
AM products in the popular media and unsubstantiated
ealth care claims seem to be driving their demand and
orcing even conventional medical practitioners to incorpo-
ate CAM therapies into their practices. In 2 nationwide
urveys conducted in 1990 and 1997, Eisenberg et al. (1,3)
ound an increased number of visits to CAM providers from
27 million to 629 million, whereas the number of visits
o primary physicians remained, in essence, unchanged
Fig. 1A). Millions of people are therefore exposed to the
isk of these potential adverse interactions, especially
ith products that contain several herbs.
The use of herbal supplements is prevalent among pa-
ients who are taking prescription medications, particularly
enior citizens (4). Yet few clinical studies have systemati-
ally assessed potential interactions between herbs and
edications (5). Most patients do not readily disclose their
se of CAM to their health care providers (1), and physi-
ians may not routinely ask about such use. As a result,
angerous herb–drug interactions may be missed. However,
otentially serious consequences might be avoided by ob-
aining a more careful history about CAM use. In this
eview, we highlight some common herbal remedies used,
heir adverse cardiovascular effects, and their potential
nteractions with cardiovascular drugs. We also discuss
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products and suggest ways to im-
prove their safety.
Search Strategy
and Selection Criteria
A search of the PubMed and
Medline databases was per-
formed for the years 1966 to
2008 using the search terms car-
diovascular agents, complemen-
ary therapies, herb–drug interaction, and cardiovascular
isease interactions to identify citations, abstracts, and
rticles on herbs and cardiovascular disease.
ardiovascular Adverse
ffects of Herbal Remedies
atients are increasingly using herbal products for purport-
dly preventive and therapeutic purposes (6). Some products
ave direct effects on the cardiovascular or hemostatic
ystem, whereas others have indirect effects through inter-
Abbreviations
and Acronyms
BPH  benign prostatic
hypertrophy
CAM  complementary and
alternative medicine
CHF  congestive heart
failure
FDA  U.S. Food and Drug
Administration
Figure 1 Comparison of Number of Visits, Costs, and Condition
(A) Annual visits to physicians versus those to complementary and alternative me
costs of CAM services by type compared with the costs of physician services and
common conditions for which CAM therapies are used in the U.S. Data from Barnes P
among adults: United States, 2002. Advance data from vital and health statistics; noctions with medications that could lead to serious conse-
uences (4). Common herbal remedies that produce adverse
ffects on the cardiovascular system include St. John’s wort,
ated Medically or by CAM
(CAM) practitioners. Adapted, with permission, from Eisenberg et al. (1). (B) The
alizations. Adapted, with permission, from Eisenberg et al. (1). (C) The most
ell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use
yattsville, MD: National Center for Health Statistics, 2004. GI  gastrointestinal.
Figure 2 Types of Complementary and
Alternative Medicine Used by U.S. Consumers
Data from Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of
complementary and alternative medicine by US adults: 1997–2002. Altern Ther
Health Med 2005;11:42–9.s Tre
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February 9, 2010:515–25 Herbal Products and Cardiovascular Diseasesotherwort, ginseng, gingko biloba, garlic, grapefruit juice,
awthorn, saw palmetto, danshen, echinacea, tetrandrine,
conite, yohimbine, gynura, licorice, and black cohosh
Table 1).
t. John’s wort. St. John’s wort is one of the top 10
est-selling herbs in the U.S. (7). It is typically used to treat
epression, anxiety, sleep disorders, the common cold,
erpes, and the human immunodeficiency virus. It is used as
topical analgesic, and even as an enema for ulcerative
olitis.
Use of St. John’s wort could potentially result in serious
dverse reactions because of its effect on drug metabolism; it
nduces the hepatic cytochrome P450 system (8), particu-
erbal Products to Avoid in Patients With Cardiovascular DiseasesTable 1 Herbal Products to Avoid in Patients With Cardiovascu
Herb Purported Use
Alfalfa Arthritis, asthma, dyspepsia, hyperlipidemia, diabetes
Aloe vera Wounds (topical), diabetes (oral)
Angelica (dong quai) Appetite loss, dyspepsia, infection
Bilberry Circulatory disorders, local inflammation, skin condition
diarrhea, arthritis
Butcher’s broom Circulatory disorders, inflammation, leg cramps
Capsicum Shingles, trigeminal and diabetic neuralgia
Fenugreek High cholesterol
Fumitory Infection, edema, hypertension, constipation
Garlic High cholesterol, hypertension, heart disease
Ginger High cholesterol, motion sickness, indigestion, antioxid
Ginkgo Poor circulation, cognitive disorder
Ginseng Aging, diminished immunity, improves mental and
physical capacity and stress tolerance
Gossypol Male contraceptive
Grapefruit juice Weight loss, to promote cardiovascular health
Green tea Improve cognitive performance, mental alertness,
weight loss, diuretic
Hawthorn CHF, hypertension
Irish moss Ulcers, gastritis
Kelp Cancer, obesity
Khella Muscle spasms
Licorice Ulcer, cirrhosis, cough, sore throat, infections
Lily of the valley CHF
Ma-huang (ephedra) Obesity, cough
Night-blooming cereus CHF
Oleander Muscle cramps, asthma, cancer, CHF, hepatitis,
psoriasis, arthritis
St. John’s wort Depression
Storphanthus CHF
Yohimbine Impotence
Only major indications, adverse effects, and interactions are listed; thus, the list is not all inclusi
CHF  congestive heart failure; COX  cyclooxygenase; MAOI  monoamine oxidase inhibitor.arly CYP3A4, an enzyme involved in oxidative metabolism Jf more than 50% of all prescription medications (Table 2)
9). Therefore, coadministration of this herb and drugs
etabolized by CYP3A4 (Table 2) should be avoided, as it
ay result in reduced bioavailability and effectiveness with
ubsequent recurrence of arrhythmia, hypertension, or other
ndesirable effects (9).
Reduced drug levels of ethinyl estradiol (10), indinavir
11), and cyclosporine (12,13) have been reported in patients
sing St. John’s wort. In 1 study of organ transplant patients,
t. John’s wort caused a decrease of almost 50% in the
oncentration of cyclosporine (14). A similar experience was
eported in renal and cardiac transplant patients who had a
eduction in the efficacy of immunosuppressants taken with St.
iseases*
Cardiac Adverse Effect of Interaction
Increases bleeding risk with warfarin
Hypokalemia causing digitalis toxicity and arrhythmia
Increases bleeding risk with warfarin
Increases bleeding risk with warfarin
Decreases effects of alpha-blockers
Increases blood pressure (with MAOI)
Increases bleeding risk with warfarin, hypoglycemia
Increases effects of beta-blockers, calcium-channel blockers, cardiac glycosides
Increases bleeding risk with warfarin
Increases bleeding risk with warfarin
Increases bleeding risk with warfarin, aspirin, or COX-2 inhibitors
Potential risk of seizures
Increases blood pressure
Decreases effects of warfarin
Hypoglycemia
Increases effects of diuretics
Hypokalemia
Increases effects of statins, calcium-channel blockers, or cyclosporines
Decreases effects of warfarin (contains vitamin K)
Potentiates action of cardiac glycosides and nitrates
Increases effects of antihypertensives
Increases effects of antihypertensive and anticoagulant agents
Increases effects of anticoagulant agents and calcium-channel blockers
Increases blood pressure
Hypokalemia
May potentiate digoxin toxicity
Increases effects of beta-blockers, calcium-channel blockers, digitalis,
quinidine, steroids
Increases heart rate and blood pressure
Increases effects of angiotensin-converting enzyme inhibitors, antiarrhythmics,
beta-blockers, calcium-channel blockers, cardiac glycosides
Heart block
Hyperkalemia
Arrhythmia
Death
Increases heart rate and blood pressure (with MAOI)
Decreases digoxin concentration
Increases effects of cardiac glycosides
Increases heart rate
Increases or decreases blood pressure*lar D
s,
antohn’s wort, with consequent transplant rejection (9,14).
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Herbal Products and Cardiovascular Diseases February 9, 2010:515–25Concomitant use of warfarin with St. John’s wort de-
reases prothrombin time, which may result in subtherapeu-
ic anticoagulation and increased risk of thromboembolism
9,10). People taking warfarin who have a history of stroke,
hrombosis, atrial fibrillation, or prosthetic cardiac valves
hould avoid the use of St. John’s wort (Table 3). Reduced
oncentrations of statins may increase the risk of cardiovas-
ular events (15). St. John’s wort can induce the multidrug
esistance gene product P-glycoprotein, which may reduce
he blood levels and efficacy of drugs such as digoxin, which
s normally excreted by this glycoprotein (16). Hypoglyce-
ia may occur with concomitant use of antidiabetes agents
17). Serotonin syndrome, a potentially life-threatening
dverse drug reaction caused by excess serotonergic activity
n the central and peripheral nervous system, has also been
eported with concomitant use of antidepressants (18–20).
otherwort. Motherwort has a long history of use in both
uropean and Asian traditional medicine because of its
urported sedative and antispasmodic properties. Tradition-
lly, it has been used for “cardiac debility,” tachycardia,
nxiety, insomnia, and amenorrhea. It is also used as a
ypotensive and a diuretic. When administered intrave-
ously, motherwort reduces platelet aggregation and fibrin-
gen levels (21). It potentiates antithrombotic and anti-
ommon Drugs Metabolizedy the CYP3A4 System*Table 2 Common Drugs Metabolizedby the CYP3A4 System*
Medication Class Drug Names
Antiarrhythmic Amiodarone, disopyramide, flecainide†,
lidocaine, mexiletine, quinidine‡
Angiotensin receptor antagonist Irbesartan
Antihistamine Loratidine, fexofenadine
Antibiotic or antimicrobial Macrolides (erythromycins), floxacins
(ciprofloxacin), azoles (itraconazole,
ketoconazole), protease inhibitors
(indinavir sulfate, ritonavir, saquinavir,
nelfinavir mesylate)
Beta-adrenergic blocker Metoprolol,† carvedilol
Calcium-channel blocker Amlodipine besylate, felodipine, nifedipine,
diltiazem, verapamil
Chemotherapeutic Cyclophosphamide, docetaxel, doxorubicin,
etoposide, ifosfamide, paclitaxel,
tamoxifen citrate, teniposide,
vinblastine sulfate, vindesine sulfate,
gefitinib
Immunosuppressant Cyclosporine, tacrolimus, sirolimus
Psychotropic Benzodiazepines (alprazolam, clonazepam,
flunitrazepam, midazolam, triazolam;
tricyclic antidepressants (amitriptyline,
clomipramine, imipramine); SSRIs
(citalopram, fluoxetine, norfluoxetine,
sertraline)
HMG-CoA reductase inhibitor
(statins)
Atorvastatin, cerivastatin, fluvastatin,
lovastatin, simvastatin
Other Cisapride, cortisol, ethinyl estradiol,
progesterone, sildenafil, terazocin,
warfarin§
List is not all inclusive. †Also by CYP2D6. ‡Also by CYP2D1. §Also by CYP2D9.
HMG-CoA  3-hydroxy-3-methylglutaryl-coenzyme A; SSRI  selective serotonin reuptake
nhibitor.latelet effects and increases the risk of bleeding (Table 3).aken with benzodiazepines, motherwort can have a syn-
rgistic sedative effect and may result in coma.
inseng. The origin of the ginseng root and its manner of
xtraction can produce wide variations in ginseng products.
inseng is advertised as an immune system stimulant that
ncreases vigor, sexual potency, and longevity, and for use as
n antidiabetes agent (9). Ginseng has both hypertensive
nd hypotensive effects, the latter caused by the enhanced
ynthesis of nitric oxide (22). In Chinese medicine, ginseng
s used for myocardial infarction, congestive heart failure
CHF), and angina pectoris; however, current evidence does
ot support its use for cardiovascular conditions.
Ginseng abuse syndrome causes hypertension, behavioral
hanges, and diarrhea (23). A nephrotoxic contaminant,
ermanium, may damage cells of the thick ascending limb
f the loop of Henle, thereby diminishing responsiveness to
oop diuretics (24). When administered with warfarin,
inseng resulted in reduced prothrombin time (25). The
nconsistency of ginseng in lowering blood glucose may be
elated to the type of preparation. Ginseng can produce
ffects similar to those of estrogen because its active com-
onents, ginsenosides, have a chemical structure similar to
hat of testosterone, estrogen, and glucocorticoids (26).
inseng should not be used by women who are pregnant or
eceiving hormone replacement therapy. Neonatal death has
een related to maternal use (27). Increased levels of digoxin
re associated with Siberian ginseng, which interferes with
he digoxin assay (Table 4).
ommonly Used Herbs That Cantentiate the Risk of Bleeding or ArrhythmogenesisTable 3 Commonly Us Herbs That CanPotentiate the Risk of Bleeding or Arrhythmogenesis
Bleeding
Alfalfa
Bilberry
Danshen
Dong quai
Fenugreek
Garlic
Ginkgo biloba
Ginseng
Motherwort
Saw palmetto
Arrhythmogenesis (QT prolongation)
Aloe vera
Bitter orange
Echinacea
Ginkgo biloba
Ginseng
Guarana
Hawthorn
Horny goat weed
Licorice
Lily of the valley
Night-blooming cereus
Oleander
RhodiolaSt. John’s wort
G
t
i
c
i
s
s
(
o
b
b
b
g
C
u
a
b
h
h
p
G
t
t
a
t
s
t
r
e
o
i
a
p
l
d
a
i
s
c
w
G
t
c
C
i
c
e
m
(
s
w
r
C
c
C
g
H
a
c
v
p
C
o
t
e
c
d
c
t
i
a
s
v
h
S
m
(
a
p
a
h
d
p
t
i
w
HI
A
a
N
519JACC Vol. 55, No. 6, 2010 Tachjian et al.
February 9, 2010:515–25 Herbal Products and Cardiovascular Diseasesinkgo. Ginkgo biloba is one of the world’s oldest living
ree species, dating back to the Permian period. Purported
ndications include conditions such as cardiovascular disease,
erebrovascular or peripheral vascular insufficiency, impotence,
nner ear dysfunction, retinopathy, pre-menstrual syndrome,
tress, depression, and dementia. Ginkgo is one of the best-
elling herbal remedies in the U.S. for cognitive impairment
7). However, early trials that suggested it had beneficial effects
n cognition were limited by inadequate methods, low num-
ers of patients, absence of hard end points, and publication
ias (28). Recent randomized trials showed no difference
etween ginkgo and placebo (28,29). A large clinical trial of
inkgo for prevention of dementia, supported by the National
enter for Complementary and Alternative Medicine, is
nderway.
The concurrent use of ginkgo with antiplatelet, antico-
gulant, or antithrombotic agents increases the risk of
leeding. Hyphema, subphrenic hematoma, and intracranial
emorrhage have been reported (9). In clinical trials, ginkgo
as also been shown to reduce the effectiveness of nicardi-
ine by interacting with the cytochrome P450 system (9).
arlic. Garlic has been mentioned in medicinal texts since
he Ebers papyrus (circa 1550 BC). It has been used for
reatment of infectious conditions because of its presumed
ntimicrobial and immune-enhancing properties. Garlic is
hought to have cholesterol-lowering and other antiathero-
clerotic and antihypertensive effects and is used for preven-
ion of cardiovascular disease (30). Despite such claims, a
ecent study concluded that raw, powdered, or aged garlic
xtract versus placebo for 6 months had no significant effect
n low-density lipoprotein cholesterol or other plasma lipids
n adults with moderate hypercholesterolemia (31). The
erbal Products That Maynterfere With Digoxin Level and AssaysTable 4 Herbal Products That MInterfere With Digoxin Level and Assays
Herb
Extent of
Interference Comments
Chan su High Active components (e.g., bufalin) cross-react
with digoxin assay
Monitoring free digoxin eliminates
interference
Danshen Moderate Falsely increases (FPIA) or falsely decreases
low levels (MEIA) of digoxin
Monitoring free digoxin eliminates
interference
Asian ginseng Moderate Falsely increases elevated (FPIA) or falsely
decreases low (MEIA) digoxin level
Monitoring free digoxin does not eliminate
interference
Siberian ginseng Moderate Falsely increases elevated (FPIA) or falsely
decreases low (MEIA) digoxin
Monitoring free digoxin does not eliminate
interference
Uzara root (diuretic) NA Increases effect with digoxin
Interferes with digoxin assay
dapted and reprinted, with permission, from Dasgupta A. Review of abnormal laboratory test results
nd toxic effects due to use of herbal medicines. Am J Clin Pathol 2003;120:127–37.
FPIA  fluorescence polarization immunoassay; MEIA  microparticle enzyme immunoassay;
A  not available.ctive component ajoene in garlic inhibits collagen-induced ilatelet aggregation (32), and garlic is used for its antiplate-
et and fibrinolytic effects in patients with cardiovascular
isease. However, the risk of bleeding in people using
nticoagulant or antiplatelet agents increases, so its concom-
tant use should be avoided (33,34). Garlic supplements
hould be discontinued about 10 days before elective surgi-
al procedures, especially by patients taking aspirin or
arfarin (33).
rapefruit juice. Grapefruit is used as a dietary interven-
ion to lose weight and improve cardiovascular health. Its
onstituents of naringenin and bergamottin inhibit the
YP3A4 enzyme in small-intestine enterocytes, which
ncreases blood levels of CYP3A4 substrate drugs, including
alcium-channel blockers, cyclosporine, statins, midazolam,
strogen, and terazosin (Table 2). The action of these
edications is potentiated by their increased bioavailability
35–38), which potentially can result in dangerous hypoten-
ion, myopathy, or liver toxicity. In post-menopausal
omen taking estrogen, grapefruit juice may increase the
isk of breast cancer by inhibiting estrogen metabolism by
YP3A4 (39). These potential interactions should be dis-
ussed with patients taking medications metabolized by the
YP3A4 system, and they should be advised to avoid
rapefruit consumption.
awthorn. Hawthorn extract is commonly used by herb-
lists for treatment of angina, CHF, bradyarrhythmia, and
erebral insufficiency. Hawthorn has positive inotropic and
asodilatory effects and is thought to increase myocardial
erfusion and reduce afterload. As an adjunct treatment for
HF, hawthorn has been reported to have beneficial effects
n symptom control and physiologic outcomes (40,41), but
he efficacy and safety of its supposed inotropic activity and
ffect on morbidity and mortality have not been systemati-
ally assessed (40). Hawthorn enhances the activity of
igitalis (42), and its concomitant use should be monitored
arefully for potential toxic effects. Hawthorn also inhibits
he biosynthesis of thromboxane A2, and it could potentially
ncrease the risk of bleeding in patients taking antiplatelet or
nticoagulant agents (9,43). Without additional data on
afety and efficacy, clinicians should discourage unsuper-
ised use of hawthorn in patients with CHF who are taking
eart failure medications.
aw palmetto. Saw palmetto is used by more than 2
illion men for treatment of benign prostatic hypertrophy
BPH) (7). It is also used as a diuretic and a urinary
ntiseptic. The exact biologic mechanism of action of saw
almetto is not clear. In vitro, it potently inhibits alpha1-
drenergic receptors (44). Despite claims that saw palmetto
elps relieve BPH symptoms, recent clinical trials did not
emonstrate any beneficial effects on BPH symptoms or
ost-void residual bladder volume (45). Additional prospec-
ive studies are needed to establish the role of herbal extracts
n alleviating BPH symptoms.
Saw palmetto inhibits cyclooxygenase and increases bleeding
ith warfarin (46). In addition, its unsupervised use can resultn cholestatic hepatitis, acute pancreatitis (47), and intraoper-
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Herbal Products and Cardiovascular Diseases February 9, 2010:515–25tive floppy iris syndrome during cataract removal because of
oss of iris tone (48). Ophthalmologists should be aware of this
mportant association so that they can take the necessary steps
o prevent surgical complications.
anshen. Danshen is used in traditional Chinese medicine for
reatment of coronary artery disease and menstrual abnormalities.
anshen reduces elimination of warfarin and inhibits cyclic
ommon Herb–Drug InteractionsTable 5 Common Herb–Drug Interactions
Herb Drug or Drug Class
Comfrey Phenobarbital
Danshen Anticoagulant or antiplatelet agents
Digoxin
Echinacea Amiodarone or ibutilide
Statins, fibrates, niacin
Ephedra Antidiabetes drugs
Class IA and class III antiarrhythmics
Beta-blockers
Monoamine oxidase inhibitors
Evening primrose oil Phenobarbital
Garlic Aspirin, clopidogrel, warfarin, or heparinoid drugs
Ginkgo biloba Antidiabetes drugs
Aspirin
Warfarin
Ginseng Antidiabetes drugs
Digoxin
Warfarin
Phenelzine sulfate
Hawthorn Digoxin
Calcium-channel blockers or nitrates
Kava Alprazolam
Licorice Spironolactone
Saw palmetto Anticoagulant or antiplatelet agents
Soy milk Warfarin
St. John’s wort Digoxin
Clopidogrel
Warfarin
Simvastatin
Paroxetine
Class IA and III antiarrhythmic agents
Cyclosporine
Theophylline
Indinavir
Yohimbine Clonidine, Guanabenz
CNS stimulants (e.g., amphetamines)
ACE inhibitors
Beta-blockers
CE  angiotensin-converting enzyme; CNS  central nervous system; HIV  human immunodefidenosine monophosphate phosphodiesterase, which results in idditive antiplatelet effects and risk of bleeding (Table 5). Con-
omitant use with warfarin increases prothrombin time (49).
anshen may also interfere with digoxin assay (Table 4); in
he absence of signs or symptoms of digoxin toxicity, the
ossibility of a false elevation of digoxin concentration
hould be explored.
chinacea. Echinacea is popularly believed to stimulate the
Interaction or Other Comments
ases metabolism of comfrey, producing a lethal metabolite from pyrrolizidine that
sults in severe hepatotoxicity
ases bleeding due to additive effects
ases side effects of digoxin
ases QT interval
ases risk of hepatotoxic effects
ases blood glucose
eases effectiveness of oral hypoglycemic agents
ases QT interval
eases effects of beta-blockers, leading to hypertension and tachycardia
rtension
eases seizure threshold
ases bleeding risk
ases hypoglycemia
ases bleeding
its PAF hemorrhage
ases hypoglycemia
feres with digoxin assay, leading to falsely increased levels
eases effectiveness of warfarin
dache
bility
mnia
ases effects of digoxin
ases vasodilatory effects
ases CNS depression
ases effects of alcohol
ases effects of spironolactone
ases bleeding
eases effectiveness of warfarin
eases serum digoxin concentration
ases activity of clopidogrel
ases bleeding
eases warfarin bioavailability and effectiveness
eases effectiveness of simvastatin
sea
argy
herence
eases effectiveness (precipitating arrhythmias)
eases cyclosporine concentration due to increased clearance (transplant rejection)
eases serum concentration
eases serum concentration (treatment failure in HIV patients)
eases blood pressure reduction effect of centrally active agents
of hypertensive crisis due to its monoamine oxidase inhibitor activity
eases effectiveness of ACE inhibitors
rtension
eases effectiveness of beta-blockers
rtension
ases heart rate
virus; PAF  platelet-activating factor.Incre
re
Incre
Incre
Incre
Incre
Incre
Decr
Incre
Decr
Hype
Decr
Incre
Incre
Incre
Inhib
Incre
Inter
Decr
Hea
Irrita
Inso
Incre
Incre
Incre
Incre
Incre
Incre
Decr
Decr
Incre
Incre
Decr
Decr
Nau
Leth
Inco
Decr
Decr
Decr
Decr
Decr
Risk
Decr
Hype
Decr
Hype
Incremmune system and prevent infections. The evidence is still
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February 9, 2010:515–25 Herbal Products and Cardiovascular Diseasesnsufficient to support clear therapeutic recommendations.
he results of a controlled double-blind study indicated that
chinacea had no clinically significant effects on rhinovirus
nfection (50). Persistent use may result in or potentiate the
epatotoxic effects of other medications (e.g., statins, fi-
rates, niacins, or amiodarone). Side effects include nausea,
izziness, dyspnea, rash, and dermatitis. Flavonoids from
chinacea may inhibit or induce cytochrome P450 enzymes,
epending on their structure and assay conditions (9).
etrandrine. Tetrandrine is a vasoactive alkaloid used in
hinese medicine to treat hypertension and angina. Its
asodilative effect is due to inhibition of the L-type calcium
hannels (51) and possible competition with other calcium-
hannel blockers (52). Tetrandrine lowers plasma glucose
nd causes hepatotoxicity and renal toxicity (53).
conite. Traditional Chinese practitioners use aconite for
ain relief caused by trigeminal and intercostal neuralgia,
heumatism, migraine, and general debilitation. Aconite
nitially stimulates and then paralyzes nerves that commu-
icate pain, touch, and temperature, producing anesthesia
ediated by numerous different alkaloids blocking sodium
urrent (54). It is also used as a mild diaphoretic and to slow
ulse rate by its effect on brainstem centers. Atrial or
entricular fibrillation, however, may result from the direct
ffect of aconite on the myocardium. Side effects occur even
fter contact with leaves or sap from Aconitum plants (or
onkshood), and can range from bradycardia and hypoten-
ion to fatal ventricular arrhythmia induced by triggered
ctivity (55,56).
ohimbine. Yohimbine is marketed for treatment of sexual
isorders and exhaustion. Many of its effects are attributed
o its alpha2-adrenergic receptor antagonist activity. Yohim-
ine increases the release of norepinephrine, resulting in
nadequate blood pressure control in people also using
ntihypertensive and diuretic agents (57) (Table 5). Use of
ohimbine is contraindicated in patients with hypertension,
ngina, and renal impairment.
ynura. Widely used in Chinese folk medicine, gynura
urportedly improves microcirculation and relieves pain; how-
ver, it has been associated with hepatic toxicity (58–61).
esultant conditions include hepatic veno-occlusive disease,
hich is characterized by painful hepatomegaly, fluid avidity,
eight gain, and jaundice (58–60). In animals, gynura has
een shown to inhibit angiotensin-converting enzyme activity,
esulting in hypotension (62).
icorice. Licorice is used as an expectorant. Modern cough
yrups often include licorice extract. It can result in
seudoaldosteronism with concomitant hypokalemia, hy-
ertension, and edema that may reduce the effectiveness of
ntihypertensive drugs (63). Licorice-induced hypokalemia
an lead to increased risk for ventricular arrhythmia, particu-
arly torsades de pointes (64,65) (Table 3). It can also poten-
iate the effects of spironolactone and digoxin (Tables 1 and 5),
nd can cause hyperglycemia, rendering antidiabetes agents less
ffective. Its ability to inhibit thrombin and platelet aggregation bnhances the risk of bleeding with antiplatelet and anticoagu-
ant agents.
lack cohosh. Black cohosh contains triterpene glycosides
nd has been used in remedies for relief of symptoms of
enopause, pre-menstrual tension, and other gynecologic
roblems. The mechanism of action is unclear. It may bind
o estrogen and serotonin receptors (66). After estrogen
eplacement therapy was shown to increase the risk of
hromboembolic and cardiovascular events and breast can-
er, sales of black cohosh supplements soared ($79 million
n 2003) (67,68). In 2006, a clinical trial supported by the
ational Center for Complementary and Alternative Med-
cine failed to show that treatments containing black cohosh
elieved menopause-associated symptoms (67). Commer-
ially available dietary supplements made from black cohosh
nhibit CYP3A4 and potentially increase the risk of adverse
ffects from some drugs (Table 2). Hepatotoxicity has been
eported (66,69), and black cohosh should not be used
uring pregnancy or lactation (9).
roblems Related to the Use of Herbal Products
he use of herbal products is complicated by numerous
roblems, as summarized below.
ack of scientific evidence of safety and efficacy. Most
erbal products have not been scientifically evaluated; thus,
nformation is limited about their pharmacokinetics, phar-
acodynamics, efficacy, and safety. Randomized controlled
rials are the best way to determine efficacy and safety;
owever, controlled trials for most herbal products are not
vailable, not demanded by consumers or health care prac-
itioners, and not required by regulatory agencies. Belief in
he safety of CAM products remains unsubstantiated, and
ven when data are available, findings are often questionable
ecause of a lack of consistency in research methods, small
umber of subjects, absence of placebo groups, inclusion of
ealthy volunteers or low-risk populations without comor-
id conditions, lack of standardization of supplements being
nvestigated, and absence of data about drug–herb interac-
ions. Thus, findings for specific herbal products are often of
imited usefulness for making decisions about efficacy or
afety.
ack of regulatory oversight. Despite the lack of scientific
vidence about the efficacy and safety of herbal products,
ore than 30,000 dietary supplements are sold in the U.S.,
ith an additional 1,000 new supplements introduced
nnually. Most patients believe that the government over-
ees the safety of CAM; but the fact is that the only
equirement is for the manufacturer to send a copy of the
roduct label to the U.S. Food and Drug Administration
FDA). A new dietary supplement or new formulation can
e introduced and marketed overnight, without significant
estriction, despite containing new, experimental, and un-
egulated herbal ingredients. The Dietary Supplement
ealth and Education Act of 1994 provides some oversightut nonetheless allows untested herbal products on the
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Herbal Products and Cardiovascular Diseases February 9, 2010:515–25arket without safety testing (70). Unfortunately, many
upplements contain ingredients or contaminants with ad-
erse effects or interactions. If these supplements were
ubject to pre-market safety testing, many would no doubt
e banned.
The FDA has identified several supplements, including
phedra, chaparral, comfrey, lobelia, and yohimbe, that have
aused serious harm, yet it took 9 years to get ephedra alone
emoved from the market (71). The other products are still
vailable for sale in stores and over the Internet. Restricting
specific substance or group of substances is not particularly
elpful because manufacturers can simply introduce new
ormulations. From 1995 to 1997, hundreds of cases of
phedra toxicity were reported to the FDA as causing
troke, myocardial infarction, seizure, and death from car-
iac arrhythmia (72). Side effects occurred in otherwise
ealthy young adults who used ephedra for energy boost and
eight loss (72). As a result, ephedra was eventually banned
y the FDA, but other structurally related sympathomi-
etic amines emerged to take its place in weight-loss and
nergy-enhancement products, such as synephrine, which is
ow the most popular ephedra replacement. It has a similar
harmacology and structure. Internet resources describe
ynephrine as an herbal supplement that stimulates fat
etabolism, suppresses appetite, and boosts caloric expen-
iture without side effects. Synephrine inhibits intestinal
ytochrome P450 and increases blood levels of many drugs
Table 2). Like ephedra and caffeine, the combination of
ynephrine and caffeine produces arrhythmogenesis, stroke,
HF, and seizures (73).
The general public regards herbal products as natural.
hus, there is a widespread yet false perception that herbal
roducts are safe. According to a 2002 nationwide Harris
nteractive poll of more than 1,000 adults, 60% of respon-
ents believed that supplements were approved by a gov-
rnmental agency before they could be sold, that warning
abels were required to list potential side effects, and that
upplement manufacturers could not make safety claims
ithout solid scientific evidence (74).
ack of quality control. The wide variations in herbal
upplement manufacturing techniques, storage methods,
nd lot-to-lot variability require urgent attention from the
DA and other regulatory agencies. The U.S. Pharmaco-
eia has been developing quality control standards, but
upplement manufacturers are not required to follow these
uidelines. Such latitude allows cheaply manufactured and
ven expired herbal products to be sold without restriction.
he variation in herbal sources and the inconsistent labeling
f ingredients continue to be of major concern. More than
0% of all herbal products fail to contain as much of their
ctive ingredients as claimed on their labels (75) or substi-
ute cheaper ingredients for more expensive ones (23).
Contamination with heavy metals, adulteration with
harmaceuticals, and prohibited animal and plant ingredi-
nts are repeatedly found in herbal products (76,77). Inten-
ional and unintentional adulteration with antibiotics, non- iteroidal anti-inflammatory drugs, hormones, and heavy
etals is common. Untested and unregulated steroids are
old to the public, including minors (78). In 2007, the FDA
ssued 9 safety alerts warning consumers to stop using 13
rands marketed as dietary supplements because testing
dentified undocumented prescription medications in them
78). Nine contained erectile dysfunction drugs such as
ildenafil or tadalafil, 3 contained lovastatin, and 1 con-
ained the weight-loss drug sibutramine.
The ramifications of using herbal supplements are some-
imes discerned through subsequent medical tests or treat-
ent. For example, colchicine has been found in the
lacenta of women taking ginkgo (79). Aristolochic acid
ephropathy has been reported in patients who took herbal
upplements without knowing that the manufacturer had
ubstituted Aristolochia for another herb (80,81). In addition
o being a renal toxin, aristolochic acid is on the World
ealth Organization’s list of human carcinogens. It is
anned from use in several European countries, but is still
eadily available in the U.S. (78,81).
The FDA guidelines for manufacturers mandate that
hey avoid contaminating products with other herbs, pesti-
ides, heavy metals, or prescription drugs (82). Nonetheless,
roducts have been repeatedly reported to contain adulter-
nt compounds and to put unknowing consumers at risk of
dverse side effects and drug interactions.
ublic misinformation. Unethical marketing techniques
ave led to false advertisements about the safety and efficacy
f the herbs reaching the public today, more so than at any
ther time. Herbal products are promoted in magazines,
ewspapers, and books, on radio and television, and through
he Internet. Herbs are advocated for treatment on the basis
f unproven, word-of-mouth traditions and beliefs. Some
romotional materials even claim that the featured product
s doctor recommended, the world’s most powerful, pat-
nted, or now presented without a prescription (even if it
ad never been prescribed). In a study of Internet marketing
f herbal products, Morris and Avorn (30) found that at
east 81% of Internet sites made 1 or more health claims;
ith more than 50% claiming to treat, prevent, diagnose, or
ure specific diseases despite regulations barring such state-
ents (30). The sale of herbal supplements can be halted
nly if the product has been proven dangerous and docu-
entary proof has been submitted to the Secretary of the
epartment of Health and Human Services. However, the
DA does not routinely test food supplements, and has to
emonstrate that a dietary supplement is “unsafe,” before it
an take action to restrict the product’s use or removal from
he marketplace (83). The burden of proof for demonstrat-
ng that a supplement is safe must be placed on manufac-
urers rather than the government or consumers, and con-
umer protection laws must be instituted.
ack of knowledge about herb– drug interactions by
atients and health care providers. Devastating effects
ue to a lack of understanding about adverse herb–drug
nteractions can occur in vulnerable populations, including
e
p
v
r
d
d
c
d
t
s
w
M
a
a
t
a
M
m
u
U
s
s
r
s
s
m
2
a
t
S
d
R
i
t
C
T
i
r
t
T
o
c
I
t
t
p
n
e
d
s
d
s
t
T
p
c
b
s
t
s
r
e
a
n
i
m
523JACC Vol. 55, No. 6, 2010 Tachjian et al.
February 9, 2010:515–25 Herbal Products and Cardiovascular Diseaseslderly persons, children, pregnant women, immunocom-
romised people (e.g., those with human immunodeficiency
irus or transplant recipients), and those with hepatic or
enal dysfunction. Most (64%) of the patients with a
iagnosis of atrial fibrillation, CHF, or ischemic heart
isease who were attending a cardiovascular clinic reported
oncomitant use of alternative therapies and prescription
rugs (84). More than one-half (58%) took supplements
hat had potential interactions with warfarin, amiodarone,
otalol, or digoxin. In a geriatric clinic, 46% of the patients
ere taking supplements with anticoagulation properties.
ost (73%) were also taking a prescription anticoagulant
nd were unaware of potential interactions. Findings from
nother study indicated that 1 in 6 adults taking conven-
ional prescription medications reported concomitant use of
t least 1 CAM product during the preceding week (37).
ore than 40% of the respondents said that taking herbal
edicine along with prescription medication was more
seful than taking either alone (85).
nder-reporting of adverse drug reactions. Most con-
umers are unlikely to attribute health problems to a
upplement that they assume is safe and natural, and are
eluctant to report an adverse effect from a self-medicated
ubstance. Supplement manufacturers also rarely report
erious adverse effects to the FDA despite federal require-
ents. Between 1990 and 1994, fewer than 10 of more than
,500 reports of adverse effects made to the FDA came from
n herbal product manufacturer. A report from the inspec-
or general of the Department of Health and Human
ervices revealed that 1% of adverse reactions caused by
ietary supplements are reported to the FDA (86) (Fig. 3).
ecent FDA post-marketing guidance for the supplement
ndustry mandates the reporting of all serious adverse events
o the FDA within 15 days (87).
Figure 3 Adverse Effects of Herbal Products
Adverse effects of (A) herbal products and (B) ephedra are underreported to the U
Rodgers GC Jr., et al. 2001 annual report of the American Association of Poison Conclusions
he use of herbal remedies in the U.S. is widespread and
ncreasing dramatically, yet current laws allow these herbal
emedies to be marketed as dietary supplements not subject
o the same regulations required for prescription drugs.
hus the purity, efficacy, and safety of herbal products are
ften unknown, and individual products may not even
ontain the amount of active ingredients listed on the label.
n addition, manufacturers seldom report adverse events to
he FDA. Manufacturers should be required to register with
he FDA and to provide evidence of good manufacturing
ractices (i.e., standardization, storage, preparation tech-
iques, and manufacturing sites). Evidence of the safety and
fficacy of the herbal product should be obtained by well-
esigned clinical trials, pre-marketing approval regarding
afety, and strict post-marketing surveillance.
Herb–drug interactions are especially relevant when car-
iovascular medications with a narrow therapeutic index,
uch as digoxin and warfarin, are coadministered with herbs
hat can potentiate or reduce pharmacologic effects (4,6).
hus, health care professionals should carefully question
atients about their use of herbal products. Treating physi-
ians are often unaware of patients’ use of such products
ecause patients are not routinely asked about it. Collecting
uch information is important, particularly in elderly pa-
ients at higher risk of adverse interactions. Physicians
hould therefore have a good knowledge base about herbal
emedies and should inquire about their use, discuss adverse
ffects, and monitor and identify possible herb–drug inter-
ctions. In addition, properly designed clinical trials are
eeded to assess the safety and efficacy of herbal remedies,
ncluding potential interactions with concurrently used
edications.
od and Drug Administration. Data from Litovitz TL, Klein-Schwartz W,
Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002;20:391–452..S. Fo
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Herbal Products and Cardiovascular Diseases February 9, 2010:515–25There is a clear need for better public and physician
nderstanding of herbal products through health education,
arly detection and management of herbal toxicities, scien-
ific scrutiny of their use, and research on their safety and
ffectiveness. Regulatory policies are also needed to protect
eople from untoward effects on their health and finances.
he principles and standards of evidence for safety and
fficacy of drugs used in conventional medicine should also
pply to herbal and other CAM products, with decisions
bout their use based on the results of scientific inquiry
ather than on long-held but untested belief systems or
raditions (88).
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